Overview


A disease-modifying treatment or drug that can slow down or stop the progression of a disorder is also called disease-modifying therapy. These treatments are different from symptomatic therapies that only treat symptoms and do not address the underlying cause. The market for disease-modifying drugs, which includes immunomodulators and anti-TNF agents, has seen significant growth in recent years. This is because it helps to slow the progression and spread of disease in many inflammatory conditions, such as rheumatoid, psoriasis, and rheumatoid. Today, there are 15 FDA-approved non-biologics as well as biologics that can be used to modify disease. In addition, there are an estimated 18 standard or biosimilar agents.

Anti-TNF drugs have always been effective in treating symptoms of conditions such as rheumatoid, psoriatic, multiple sclerosis, Crohn's, and psoriatic. They also prevent the development of other diseases. With the introduction of disease-modifying medications, however, the landscape has changed. There are many new disease-modifying drugs that are currently in development. They will all offer valuable options to patients suffering from these diseases, which will help drive the market for a disease-modifying agent in the forecasted timeline. The disease-modifying agent market faces many challenges. There are a few factors that could hinder the growth of this market, such as drug recalls by the FDA and EMA. Globally, multiple sclerosis-modifying agents are becoming more expensive.

In recent years, multiple sclerosis-modifying drugs have seen their prices rise to the top of all disease-related drug lists. Both rising prices and new disease-modifying medications have led to an increase in overall spending on disease-modifying medicines. Although there are many obstacles, there is still much to be done. The market for anti-TNFs is highly competitive, with many new entrants looking to modify disease. As the first-line medication, there has been an increase in the usage of disease-modifying agents. One of the first anti-rheumatic drugs used in a patient with rheumatoid arthritis was a disease-modifying drug. Methotrexate is now an anchor treatment for rheumatoid arthritis. Alzheimer's disease is also a growing concern globally, with a rising treatment cost and burden for both the government as well as the population.

Alzheimer's is a progressive neurodegenerative condition that currently causes dementia. This unmet demand will offer a bright opportunity to launch a disease-modifying drug. This is not a "cure" and prevents descent. Instead, disease modification refers specifically to a permanent modification in a disease that will delay or slow down the onset of symptoms. No effective treatment for progressive forms of multiple sclerosis has been developed. There are currently no treatments. There is no cure. Parents must manage injection issues. This is a critical time when oral disease-modifying medications for multiple sclerosis can be available. Osteoarthritis can also be treated with disease-modifying agents, but they are still in clinical trials. There is a dire need for a drug to treat osteoarthritis. The combination of direct medical expenses, pain, suffering, and loss in productivity at work make osteoarthritis a significant social and economic problem for poor patients and health systems.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Disease-Modifying Agents Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Disease-Modifying Agents Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Biogen Inc.
  • Pharmascience Inc.
  • Elan Pharma India Pvt Ltd.
  • Fresenius Kabi
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd.
  • Hospira, Inc.
  • Accord Healthcare Inc.
  • Nordic Group Bv
  • Antares Pharma, Inc.
  • Sanofi Aventis
  • Pharmascience Inc.
  • Ascend Laboratories Ltd
  • Novartis International AG
  • Strides Pharma Science Limited

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Interferon Beta-1a/ß
  • Natalizumab
  • Mitoxantrone
  • Glatiramer Acetate
  • Fingolimod
  • Dimethyl Fumarate
  • Ocrelizumab
  • Teriflunomide
  • Ciclosporin
  • Cyclophosphamide
  • Hydroxychloroquine
  • Leflunomide
  • Methotrexate
  • Mycophenolate
  • Sulfasalazine
  • Others

By Indication

  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Systemic Sclerosis
  • Cancer
  • Others

By Route of Administration

  • Oral
  • Infusion
  • Subcutaneous
  • Intravenous

By Therapy Type

  • Monotherapy
  • Combination Therapy

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Disease-Modifying Agents Market By Drug Class, By Indication, By Route of Administration, By Therapy Type, By Distribution Channels and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Disease-Modifying Agents Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Disease-Modifying Agents Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Disease-Modifying Agents Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Disease-Modifying Agents Market, By Drug Class Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Interferon Beta-1a/ß
        2. Natalizumab
        3. Mitoxantrone
        4. Glatiramer Acetate
        5. Fingolimod
        6. Dimethyl Fumarate
        7. Ocrelizumab
        8. Teriflunomide
        9. Ciclosporin
        10. Cyclophosphamide
        11. Hydroxychloroquine
        12. Leflunomide
        13. Methotrexate
        14. Mycophenolate
        15. Sulfasalazine
        16. Others

  • 8.   Disease-Modifying Agents Market, By Indication Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Multiple Sclerosis
        2. Rheumatoid Arthritis
        3. Psoriatic Arthritis
        4. Ankylosing Spondylitis
        5. Systemic Sclerosis
        6. Cancer
        7. Others

  • 9.   Disease-Modifying Agents Market, By Route of Administration Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Oral
        2. Infusion
        3. Subcutaneous
        4. Intravenous

  • 10.   Disease-Modifying Agents Market, By Therapy Types Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Monotherapy
        2. Combination Therapy

  • 11.   Disease-Modifying Agents Market, By Distribution Channels Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 12.   North America Disease-Modifying Agents Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 13.   Latin America Disease-Modifying Agents Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 14.   Europe Disease-Modifying Agents Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 15.   Asia Pacific Disease-Modifying Agents Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 16.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Biogen Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Pharmascience Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Elan Pharma India Pvt Ltd.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Fresenius Kabi
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Teva Pharmaceutical Industries Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Hospira, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Accord Healthcare Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Nordic Group Bv
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Antares Pharma, Inc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Sanofi Aventis
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pharmascience Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Ascend Laboratories Ltd
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Novartis International AG
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Strides Pharma Science Limited
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients